UP!

AAVL $4.14   View long term graphs

Avalanche Biotechnologies is a publicly traded (NASDAQ:AAVL) biotechnology company in the NASDAQ Biotechnology Index that is worth 245 million that is dedicated to diseases of the eye. This includes macular degeneration, retinal vein occlusion, diabetic macular edema, and others.

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q2 2016 2016-09-03 Future report Set alerts
Q1 2016 2016-06-03 Future report Set alerts
Q4 2015 2016-03-03 0.00 -0.55
Q3 2015 2015-11-09 0.00 -0.55
Q2 2015 2015-08-13 0.00 -0.38
Q1 2015 2015-05-13 0.00 -0.38
Q4 2014 2015-03-05 0.00 -0.46
Q3 2014 2014-11-12 0.00 -0.39
Q2 2014 2014-09-11 0.00 -0.24
Q1 2014 2014-07-21 0.00 -0.08

Ratings

2016-03-07 Reiterated Rating Piper Jaffray Buy $15.00
2016-03-01 Reiterated Rating Chardan Capital Buy $12.50 to $9.00
2016-02-18 Reiterated Rating Piper Jaffray Buy $15.00
2016-02-02 Lower Price Target Jefferies Group Buy $20.00 to $12.00
2016-01-07 Reiterated Rating Piper Jaffray Overweight $25.00 to $15.00
2015-08-17 Upgrade Chardan Capital Neutral to Buy $17.50
2015-08-14 Lower Price Target Jefferies Group Buy $51.00 to $20.00
2015-08-14 Reiterated Rating Piper Jaffray Overweight $30.00 to $25.00
2015-08-07 Lower Price Target Piper Jaffray Overweight $52.00 to $30.00
2015-07-27 Reiterated Rating Chardan Capital Neutral $17.50
2015-06-23 Upgrade Chardan Capital Sell to Neutral $20.00
2015-06-17 Reiterated Rating Piper Jaffray Overweight $52.00
2015-06-17 Reiterated Rating Cowen and Company Outperform $55.00
2015-06-17 Lower Price Target SunTrust Buy to Neutral $60.00 to $25.00
2015-06-16 Downgrade Chardan Capital Neutral to Sell $40.00 to $20.00
2015-06-16 Downgrade SunTrust Buy to Neutral $60.00 to $25.00
2015-06-16 Reiterated Rating Jefferies Group Buy $51.00
2015-06-16 Downgrade William Blair Outperform to Market Perform $53.00 to $24.00
2015-06-03 Reiterated Rating Piper Jaffray Overweight $52.00
2015-05-23 Reiterated Rating Jefferies Group Buy $51.00
2015-05-15 Reiterated Rating Piper Jaffray Overweight $52.00
2015-03-26 Boost Price Target Jefferies Group Buy $46.00 to $51.00
2015-03-26 Reiterated Rating Chardan Capital Hold $40.00
2015-03-26 Boost Price Target Piper Jaffray Overweight $52.00
2015-03-09 Initiated Coverage SunTrust Buy $60.00
2015-03-09 Reiterated Rating Piper Jaffray Overweight $47.00
2015-02-19 Initiated Coverage Chardan Capital Neutral $40.00
2015-02-13 Boost Price Target Jefferies Group Buy $40.00 to $46.00
2014-12-02 Boost Price Target Piper Jaffray $47.00
2014-08-25 Initiated Coverage William Blair Outperform $52.00
2014-08-25 Initiated Coverage Cowen and Company Outperform $45.00
2014-08-25 Initiated Coverage Piper Jaffray Overweight $39.00
2014-08-25 Initiated Coverage Jefferies Group Buy $40.00
2016-03-07 Reiterated Rating Piper Jaffray Buy $15.00
2016-03-01 Reiterated Rating Chardan Capital Buy $12.50 to $9.00
2016-02-18 Reiterated Rating Piper Jaffray Buy $15.00
2016-02-02 Lower Price Target Jefferies Group Buy $20.00 to $12.00
2016-01-07 Reiterated Rating Piper Jaffray Overweight $25.00 to $15.00

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Funds

In AAVL 2 funds of 2183 total. Show all

Fund name Ticker shares
CITY NATIONAL BANK 10654
SHAPIRO ROBERT N 104

Major Shareholders

Name Relationship Total Shares Holding stocks
Zygtech, LLC 10.95%  (2438176) AAVL /
Venrock Associates VI, L.P. 10.63%  (2365471) AAVL /
Venrock Healthcare Capital Partners II, L.P. 10.63%  (2365471) AAVL /
REGENERON PHARMACEUTICALS INC 8.13%  (1809098) AAVL / REGN /
Salzman Amber President and COO 4.01%  (891766) AAVL /
Flynn James E Possible Members of 10% Group 2.82%  (627267) AAVL / ALIM / ASPX / ATRS / AUXL / AXGN / CASM / CYCC / DRNA / EHTH / EMAG / FIXX / HITK / LOXO / NURO / PRTO / REPH / RIGL / STRM / TRGT / TWTI / VNDA / XNPT /
Finer Mitchell H. 2.71%  (603069) AAVL / BLUE /
Blumenkranz Mark S. 2.39%  (531322) AAVL /
Schwartz Steven Daniel 1.79%  (398991) AAVL /
Gasmi Mehdi VP, Pharmaceutical Development 1.30%  (289535) AAVL /
Chalberg Thomas W. Chief Executive Officer 1.16%  (258988) AAVL /
PATTERSON LEONE D CFO 0.81%  (180000) AAVL / TSPT /
Barone Samuel B. Chief Medical Officer 0.77%  (172335) AAVL /
Rubio Roman G. SVP, Translational Medicine 0.74%  (165650) AAVL /
Braun Shirley VP, Human Resources 0.72%  (161140) AAVL /
GUERIN JOHN PATRICK ET AL 0.67%  (150000) AAVL / DJCO /
Countouriotis Athena SVP, Chief Medical Officer 0.67%  (150000) AAVL / AMBI / HALO / TROV /
Hull Hans SVP, Legal and Corp. Dev. 0.62%  (137210) AAVL /
Swartzburg Michael Principal Accounting Officer 0.37%  (82113) AAVL /
Spivey Richard N. 0.32%  (70804) AAVL /
Woiwode Thomas 0.32%  (70380) AAVL /
Machado Clarence Patrick 0.31%  (68182) AAVL / CMRX / ECYT / MDVN / SCYX / TKMR /
Carter Eric G 0.22%  (48000) AAVL / ALDR /
Bain Linda Chief Financial Officer 0.19%  (41930) AAVL / BLUE /
Wachter Paul 0.14%  (31951) AAVL / TWX / VA /
Cleveland Paul B President and CEO 0.10%  (22727) AAVL / AFFY / ALDR / CLDN / SGMO /
MCLAUGHLIN JOHN PETER 0.05%  (10333) AAVL / PDLI / SGEN /

Comments